Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 Reservoir (REDUC)
An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART
Sponsor: Bionor Immuno AS
This PHASE1/PHASE2 trial investigates HIV I Infection and is currently completed. Bionor Immuno AS leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
May 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Feb 2017 — May 2017 [monthly]
Unknown Status PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1_PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bionor Immuno AS
- Celgene Corporation
For direct contact, visit the study record on ClinicalTrials.gov .